ÈËÆÞÖгöÊÓƵ

Journal Article

1. Dindinger-Hill K, Hu S, Hickman A, Choudry M, Vehawn J, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Kohli M, ONeil B, Schmidt B, Dechet C, Hashibe M, Sanchez A (2024). Association of Baseline Pre-Diagnosis and Post-Diagnosis Obesity and Weight Change with Cardiovascular Risk and Survival Among Nonmetastatic Prostate Cancer Survivors. Clin Genitourin Cancer, 22(3), 102057. ()
2. Dindinger-Hill K, Horns J, Ambrose J, Vehawn J, Choudry M, Hunt TC, Chipman J, Haaland B, Li J, Hanson HA, ONeil B (2024). Effect of ÈËÆÞÖгöÊÓƵ Service Area on Primary Care Physician Provision of Low-Value Cancer Screening. Ann Intern Med, 177(5), 583-591. ()
3. Choudry M, Dindinger-Hill K, Ambrose J, Horns J, Vehawn J, Gill H, Murray NZ, Hunt TC, Martin C, Haaland B, Chipman J, Hanson HA, ONeil BB (2024). Urban relatives ameliorate survival disparities for genitourinary cancer in rural patients. Cancer Med, 13(5), e7058. ()
4. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, Talwar R, Morgans AK, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, ONeil BB, Koyama T, Hoffman KE, Barocas DA (2024). Functional Outcomes After Localized Prostate Cancer Treatment. JAMA, 331(4), 302-317. ()
5. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, ONeil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB (2023). Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. ()
6. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Haaland B, Porucznik CA, Gren LH, Sanchez A, Lloyd S, ONeil B, Hashibe M (2023). Mental health outcomes in a population-based cohort of patients with prostate cancer. J Natl Cancer Inst, 116(3), 445-454. ()
7. Nielsen S, ONeil B, Chang CP, Mark B, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Henry NL, Lloyd S, Hashibe M (2023). Determining the association of rurality and cardiovascular disease among prostate cancer survivors. Urol Oncol, 41(10), 429.e15-429.e23. ()
8. Huang D, Chang CE, Newman M, Deshmukh V, Snyder J, Date A, Galvao C, Lloyd S, Henry NL, ONeil B, Hashibe M (2023). Adverse health outcomes among rural prostate cancer survivors: A population-based study. Cancer Epidemiol, 86, 102430. ()
9. Lange SM, Vehawn J, Choudry MM, Ambrose JP, Cluff CM, Haaland BA, Paudel N, Chipman J, Hanson HA, ONeil BB (2023). Low-Value Prostate Cancer Screening Among Young Men With Private Insurance. Urol Pract, 101097UPJ0000000000000461. ()
10. Hu S, Chang CP, Snyder J, Deshmukh V, Newman M, Date A, Galvao C, Porucznik CA, Gren LH, Sanchez A, Lloyd S, Haaland B, ONeil B, Hashibe M (2023). Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer. JCO Clin Cancer Inform, 7, e2300083. ()
11. ONeil B, Dindinger-Hill K, Gill H, Coombs L, Haaland B, Ying J, Nelson RE, McPherson J, Kirchhoff AC, Ulrich CM, Huber J, Beck A, Mooney K (2023). Cost and Utilization Outcomes in Huntsman at Home, a Novel Oncology Hospital at Home Program. J Am Med Dir Assoc, 25(4), 610-613. ()
12. Harper J, Hunt T, Choudry M, Kapron AL, Cooney KA, Martin C, Ambrose J, ONeil B (2023). Clinician interest in clinical decision support for PSA-based prostate cancer screening. Urol Oncol, 41(3), 145.e17-145.e23. ()
13. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas DA (2022). Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. ()
14. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2022). Reply by Authors. J Urol, 208(6), 1239. ()
15. Samora NL, Wallis CJD, Huang LC, Tallman JE, Zhao Z, Hoffman K, Morgans A, Cooperberg M, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan S, ONeil B, Paddock LE, Stroup A, Wu XC, Koyama T, Penson DF, Barocas DA (2022). Association between body mass index and localized prostate cancer management and disease-specific quality of life. BJUI Compass, 4(2), 223-233. ()
16. Lange SM, Choudry MM, Hunt TC, Ambrose JP, Haaland BA, Lowrance WT, Hanson HA, ONeil BB (2022). Impact of choosing wisely on imaging in men with newly diagnosed prostate cancer. Urol Oncol. ()
17. Joyce DD, Wallis CJD, Huang LC, Hoffman KE, Zhao Z, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2022). The Association between Financial Toxicity and Treatment Regret in Men with Localized Prostate Cancer. JNCI Cancer Spectr. ()
18. Harper JB, Greenberg SE, Hunt TC, Cooney KA, ONeil BB (2022). Initial outcomes and insights from a novel high-risk prostate cancer screening clinic. Prostate. ()
19. De B, Pasalic D, Barocas DA, Wallis CJD, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2022). Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study. J Urol, 101097JU0000000000002902. ()
20. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. ()
21. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2022). Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis. ()
22. Vehawn J, ONeil B (2021). Identifying Top Talent to Improve Prostatectomy Sexual Outcomes: Is the Juice Worth the Squeeze? JAMA Surg, 157(2), 144-145. ()
23. Luckenbaugh AN, Wallis CJD, Huang LC, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana AA, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Penson DF, Barocas DA (2022). Association Between Treatment for Localized Prostate Cancer and Mental ÈËÆÞÖгöÊÓƵ Outcomes. J Urol, 207, 101097JU0000000000002370. ()
24. Slade AD, Cardinal JR, Martin CR, Presson AP, Allen CD, Lowrance WT, Dechet CB, ONeil BB (2021). Feasibility of wearable activity trackers in cystectomy patients to monitor for postoperative complications. Curr Urol, 15(4), 209-213. ()
25. Hunt TC, Ambrose JP, Haaland B, Kawamoto K, Dechet CB, Lowrance WT, Hanson HA, ONeil BB (2021). Decision fatigue in low-value prostate cancer screening. Cancer, 127(18), 3343-3353. ()
26. Dorff TB, ONeil B, Hoffman KE, Lin DW, Loughlin KR, DallEra M (2021). 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol, 39(9), 521-527. ()
27. Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned ÈËÆÞÖгöÊÓƵ Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), 2586-2593. ()
28. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2021). Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urol Oncol, 40, 56.e1-56.e8. ()
29. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2021). Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 127(11), 1912-1925. ()
30. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, ONeil BB, Tward JD (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol, 5. ()
31. Stone BV, Laviana AA, Luckenbaugh AN, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Joyce DD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. J Urol, 205(3), 761-768. ()
32. Lange SM, Ambrose JP, Flynn MC, Lowrance WT, Hanson HA, ONeil BB (2021). Prostate-specific antigen testing among young men: an opportunity to improve value. Cancer Med, 10(6), 2075-2079. ()
33. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol, 204(6), 1236-1241. ()
34. Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urol Oncol, 38(12), 930.e23-930.e32. ()
35. Klett DE, ONeil B (2020). Transurethral Resection of a Bladder Tumor in Pregnancy: Decidual Reaction Bladder Endometriosis. J Endourol Case Rep, 6(3), 132-134. ()
36. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol, 78(2), 248-255. ()
37. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5. ()
38. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6. ()
39. Leiser CL, Taddie M, Hemmert R, Richards Steed R, VanDerslice JA, Henry K, Ambrose J, ONeil B, Smith KR, Hanson HA (2020). Spatial clusters of cancer incidence: analyzing 1940 census data linked to 1966-2017 cancer records. Cancer Causes Control, 31(7), 609-615. ()
40. Oswald N, Lin T, Haaland B, Flynn M, Kawamoto K, Cooney KA, Lowrance W, Hanson HA, ONeil B (2020). Factors associated with appropriate and low-value PSA testing. Cancer Epidemiol, 66, 101724. ()
41. Leiser CL, Anderson RE, Martin C, Hanson HA, ONeil B (2020). Combining Drive Time and Urologist Density to Understand Access to Urologic Care. Urology, 139, 78-83. ()
42. Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926. ()
43. Jalali A, Martin C, Nelson RE, Vanneman ME, Martin BI, Cooney KA, Waitzman NJ, ONeil B (2019). Provider Practice Competition and Adoption of Medicare's Oncology Care Model. Med Care, 58(2), 154-160. ()
44. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA (2020). Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323(2), 149-163. ()
45. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019). Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes? J Urol, 202(6), 1150-1158. ()
46. Hanson HA, Martin C, ONeil B, Leiser CL, Mayer EN, Smith KR, Lowrance WT (2019). The Relative Importance of Race Compared to ÈËÆÞÖгöÊÓƵ Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol, 202(6), 1209-1216. ()
47. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098. ()
48. Martin C, ONeil B, Lowrance W, Leiser C, Mayer E, Smith K, Hanson H (2019). The Relative Importance of Race Compared to ÈËÆÞÖгöÊÓƵcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol.
49. Laviana A, Hernandez A, Zhao Z, Huang L, Koyama T, Conwill R, Feurer I, Hoffman K, Goodman M, Hamilton A, Wu X, Paddock L, Stroup A, Cooperberg M, Hashibe M, ONeil B, Penson D, Barocas D (2019). Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes? J Urol.
50. Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, ONeil B (2018). Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making. J Urol, 201(4), 751-758. ()
51. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039. ()
52. ONeil B, Hoffman KE, Koyama T, Alvarez JR, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Kaplan SH, Hashibe M, Stanford JL, Stroup AM, Paddock LE, Chen V, Wu XC, Resnick MJ, Penson DF, Barocas DA (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. Urol Pract, 5(6), 471-479. ()
53. ONeil B, Martin C, Kapron A, Flynn M, Kawamoto K, Cooney KA (2018). Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiol, 56, 112-117. ()
54. Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533. ()
55. ONeil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The influence of provider characteristics and market forces on response to financial incentives. Am J Manag Care, 23(11), 662-667. ()
56. ONeil BB, Hoffman KE, Tasuki K, et al (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiotherapy Versus External Beam Radiotherapy of the Mid-1990's for Localized Prostate Cancer. Urol Pract.
57. Martin C, Leiser CL, ONeil BB, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A population-Based Case-Control Study. J Natl Cancer Inst.
58. ONeil B, Maughan B (2017). A More Common Massive Retroperitoneal Mass. JAMA Surg, 152(8), 802-803. ()
59. ONeil B, Tyson MD, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives.
60. Sohn W, Graves AJ, Tyson MD, ONeil BB, Chang SS, Ni D, Barocas DA, Penson DF, Resnick MJ (2016). An Empiric Evaluation of the Effect of Variation in Intensity of Follow-Up for Surgically Treated Renal Neoplasms: Estimating Value in Survivorship Care. J Urol.
61. ONeil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 195(2), 321-9. ()
62. ONeil BB, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2015). Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. J Natl Cancer Inst, 108(2).
63. ONeil BB, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, and Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 196.
64. ONeil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-63. ()

Review

1. Lange S, ONeil B (2021). Increasing the value of PSA through improved implementation. [Review]. Urol Oncol. ()

Conference Proceedings

1. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, ONeil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol, United States, 38(24), 2798-2811. ()

Commentary

1. Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Kaplan SH, Greenfield S, Luckenbaugh AN, Klaassen Z, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Hoffman KE, Barocas DA (2022). Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncol, 8(1), 50-59. ()

Editorial

1. Hunt TC, ONeil BB (2020). Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening. Eur Urol, 77(4), 400-402. ()

Letter

1. Hanson HA, Martin C, Leiser CL, ONeil B, Smith KR (2018). Response to K. Hemminki et al. [Letter to the editor]. J Natl Cancer Inst, 110(11), 1279. ()
2. ONeil B, Lowrance WT, Heilbrun ME (2017). PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors. [Letter to the editor]. JAMA, 318(16), 1614. ()

Abstract

1. ONeil B, Anderson R, Martin C, Leiser C, Hanson H (2019). A Novel Approach to Identify Disparities in Access to Urologic Care Based Upon Driving TIme [Abstract].
2. Greenberg S, Tward J, Cooney K, Pappas L, ONeil B (2019). Germline genetic testing in men with prostate cancer: clinical characteristics and testing outcomes in a newly indicated population [Abstract].
3. Armstrong J, Martin C, ONeil B, Dechet C, Morton K, Lowrance W (2018). Fluciclovine PET CT Detection of Biochemical Recurrent Prostate Cancer at Specific PSA Thresholds After Definitive Treatment [Abstract]. WSAUA.
4. Jalali A, Nelson R, Vanneman M, Martin C, Martin B, Waitzman N, ONeil BB (06/25/2018). Provider Practice Competition and Adoption of Medicare's Oncology Care Model [Abstract]. AcademyÈËÆÞÖгöÊÓƵ.
5. Hanson H, Leiser C, Martin C, ONeil BB, Lowrance W, Alter O, Gupta S, Kohlman W, Greenberg W, Smith K, Camp N (04/2018). Redefining the Bladder Cancer Phenotype Using Patterns of Familial Risk [Abstract]. Journal of Urology, 199(4).
6. Martin C, ONeil BB, Kapron A, Kawamoto K, Lowrance W, Flynn M, Cooney K (04/01/2018). Rate of Discordant PSA Testing Among Varied Guidelines: Identifying Targetable Inefficiencies in Our ÈËÆÞÖгöÊÓƵ System [Abstract]. Journal of Urology, 199(4).
7. Martin CM, ONeil BB, Kapron A, Flynn M, Kawamoto K, Lowrance WT, Cooney K (2017). Measuring PSA Screening Quality at the ÈËÆÞÖгöÊÓƵ System Level: Potental Areas for Improvement [Abstract]. Society of Urologic Oncology.

Other

1. Tallman JE, Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Barocas DA (2023). Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. England. ()
2. Tallman JE, Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2023). Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer Prostatic Dis (26(1), p. 214). England. ()

News

• How ÈËÆÞÖгöÊÓƵy Is Your Prostate?
• ÈËÆÞÖгöÊÓƵier Alternatives to the Senate Candy Drawer

Huntsman Cancer Institute News

• How Personal Inspiration Led to a Career of Saving Lives